Anthony Schwartz, PhD

CEO @morphiexbio, EIR @Hibiscusbio, ImmuneOncology Inventor (TLR/#CD47), FDA Aprvl, @JohnsHopkins, former @NCIResearchCtr, Bio Consultant

[Anthony Schwartz, PhD @aschwartzphd]

So cool to see our accelerator @Mayflower_Bio & @MayoClinic featured in the WSJ! https://t.co/jVMEvsQ0Qv via @WSJ

[Michael Torres @Mykalt45]

Off-site was super productive for us! Building worldwide!
#twitter https://t.co/T6VzLyCiHs

[Molecule @Molecule_sci]

Science is getting faster, more modular, and increasingly run by autonomous agents.

@DeSciBerlin returns for its 5th edition on June 18-19, in the heart of Kreuzberg during Berlin Blockchain Week. Two days built around scientific singularity and agentic science, for scientists, AI engineers, biotech founders, and anyone working toward a more open, accelerated research economy.

On the main stage:
> AI robotics in the wet lab
> Peptide discovery by AI agents
> Agentic swarms for science
> Longevity and rejuvenation
> Lessons from the biotech hedge fund manager
> and more

Plus hands-on workshops:
> Decentralized Science onboarding for academic researchers
> Vibecoding for science: getting useful research out of AI
> Branding and marketing for your project

The next decade of science is being shaped in rooms like this one. We're looking forward to hosting you.

[Jesse Landry @JesseDLandry]

Genetic medicine is starting to attack stop signals directly.

@artan_bio raised $200K in Seed funding as @aschwartzphd and @Mykalt45 advance ARTAN-102, an engineered suppressor tRNA platform designed to address nonsense mutations linked to genetic disease.

The next biotech winners will not always start with massive rounds. They will start with validated science strong enough to keep moving toward preclinical proof.

[Brian Bodemann @BTC_Biotech_guy]

ARTAN Bio raises $200,000 in decentralized funding. https://t.co/yzGRWhN3Hc

[Michael Torres @Mykalt45]

@artan_bio Raises $200,000 in Decentralized Funding to Advance Longevity Science Through Mutation-Specific Codon Su... https://t.co/WHvO0iaFej

Crypto + Biotech = A real thing. Excited for $vitarna token holders. We’re going to make waves in longevity. No need for $100Ms. CrossBridge flipped the script!

[Michael Torres @Mykalt45]

Excited for @aschwartzphd to share more of our work @artan_bio at the @NFCsummit in Lisbon. Artan isn’t just cool science in the longevity space, we’re creating new trails in biotech + crypto space with our $vitarna token. Kudos to @Molecule_sci and @vitadao for support this effort!

[Adam Feuerstein ✡️ @adamfeuerstein]

Incredible #ASCO26 moment.

Dr. Brian Wolpin, presenter of the daraxonrasib study, received a standing ovation DURING his talk after he stated the survival benefit for PDAC patients. It was sustained. Cheering. I have never see anything like it in the middle of a talk. $RVMD

[Anthony Schwartz, PhD @aschwartzphd]

@Mykalt45 @brunolarvol It’s like the day we went from 56k modems to fiber. Never going back!

[Adam Feuerstein ✡️ @adamfeuerstein]

Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion https://t.co/ZtSlxwaqbV via @ADeAngelis_bio

[Anthony Schwartz, PhD @aschwartzphd]

I'm looking forward to presenting @artan_bio's longevity pipeline and our decentralized model, which has helped us accelerate our work faster than traditional funding modalities.

Longevity Day at @NFCsummit, Lisbon; June 4th, 2026.

@vitarnabio @vitadao #Desci #longevity

[Michael Torres @Mykalt45]

Thanks @bradloncar for highlighting my work! I do think there’s interesting concepts in the DeSci space. Doing my part to shed light into it. @vitarnabio @vitadao @Molecule_sci @artan_bio

[Michael Torres @Mykalt45]

Get smarter about longevity folks.

[BiotechTV @BiotechTV]

𝐀𝐒𝐆𝐂𝐓 𝟐𝟎𝟐𝟔: @Mykalt45 isn't slowing down after selling his antibody-drug conjugate company to Eli Lilly. Here's his gene therapy play.

Full video: https://t.co/ye7YH2VnXj

[Adam Feuerstein ✡️ @adamfeuerstein]

Finally, best news of the morning (and something you didn't expect so soon)...

Revolution Medicines $RVMD daraxonrasib Ph3 results in second-line pancreatic cancer.

Median overall survival in ITT patients (KRAS mutants + wild type combined) Dara 13.2 months vs chemo 6.7 months.

OS Hazard ratio 0.40

[VitaDAO 💛 @vitadao]

first stop codon tRNA drug just entered human trials

@vitarnabio has been working on this for 2 years. mutation-specific suppression targeting arginine nonsense mutations in p53 + DNA repair genes.

@VitaDAO funded it early

[Eric Topol @EricTopol]

The $70 billion/year industry in the US with zero evidence of benefit in healthy people and thousands of paid influencers, by @saraashleyo
gift link https://t.co/8Ypve7QBXl

[Dr. Spencer Nadolsky @DrNadolsky]

Person: I would never take the experimental jab!

Same person: So anyway, I injected 46 different peptides yesterday, none of which have any human RCT data nor come from an fda approved manufacturer.

[Massimo @Rainmaker1973]

104 yr old WW2 Veteran performs the national anthem on saxophone

https://t.co/5BEfBmnGPm

[Michael Torres @Mykalt45]

Merry Christmas $VitaRNA family! We’ve got some cool stuff cooking! Artan-102 is a completely different approach to addressing aging than what’s out there. All of my posts above speak to the science! 2026 is going to 🔥!

https://t.co/musiWeLGOq

[Michael Torres @Mykalt45]

Attention $VitaRNA token holders: New Nature paper further supports our work: “Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma”
https://t.co/gTeuGShH5T

Using deep WGS across >1,000 tumors, this study identifies an endogenous genome-destabilizing program driven by LINE-1 (L1) reactivation that accelerates disease evolution. @vitadao @vitarnabio @Molecule_sci @BioProtocol